Koninklijke Philips N.V. (PHG) Balance Sheet

The expansion in equity over the last four quarters appears driven largely by retained earnings growth, which moved from $3.2B to $3.3B with intermittent dips, indicating only modest internal capital generation. Total liabilities remain near $15-17B across the period, so the improvement in the equity base is incremental rather than transformative. Investors should monitor whether the balance sheet trajectory reflects durable earnings retention or primarily reflects the timing of litigation-related accruals.

The leverage reduction appears to come more from equity growth than from debt repayment, since total debt has not declined meaningfully across the ten quarters. A D/E ratio near 0.70 is manageable for an industrial healthcare manufacturer, but it leaves limited headroom if litigation settlements require large cash outflows. The debt profile warrants further investigation into maturity structure, as the reported figures do not disclose refinancing timing.

A current ratio near 1.3 provides adequate short-term coverage, yet the cash balance of $2.8B in 2026Q3 represents only a fraction of total liabilities of $16.7B. The sharp swing in cash from $1.2B in 2025Q1 to $2.8B in 2025Q4 suggests liquidity is sensitive to working capital timing. Investors should view the current liquidity position as adequate under normal conditions but potentially strained if a large litigation payment coincides with weaker operating cash flow.

The high goodwill share implies that a material portion of the balance sheet rests on the value assigned to past acquisitions, which may be vulnerable to impairment if the Diagnosis and Treatment or Connected Care businesses underperform. Goodwill declined from $10.4B in 2024Q4 to $9.9B in 2026Q3, which may reflect currency effects or divestiture activity rather than operational impairment. The relatively stable PP&E base suggests an asset-light manufacturing footprint, though the goodwill concentration warrants continued scrutiny.